News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Way overblown on the hair color change & neutropenia side effects from the trial should of waited a little bit longer will buy more they want to play mind games and bring it down the 52 week low. Great Team CASH to fund through phase 3 and a molecule that is next level.
Celldex ACAAI 12 Week CIndU Conference Call & Webcast
Oct 28, 2024 at 8:00 AM EDT
https://ir.celldex.com/static-files/86311fa1-d1e8-45b7-ad38-d557ff40c836
$CLDX
just loaded another 12 pack.
$CLDX
Expect this one to double or triple from here!
$CLDX
A few years ago CLDX was $4.00
Been my best year in biotech investing Viking, Summit and Capr.
$CLDX
Loaded a nice stash under $30.00 yesterday!
$CLDX
CLDX range bound
CLDX new 52 week high
CLDX new 52 week high
|
Followers
|
90
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1925
|
|
Created
|
05/29/02
|
Type
|
Free
|
| Moderators | |||
Celldex Therapeutics, Inc. (CLDX)
http://www.celldextherapeutics.com
Company Information:
Celldex Therapeutics, Inc.
222 Cameron Drive
Suite 400
Phillipsburg, NJ. 08865
Phone: 908-454-7120
Fax: 908-454-1911
CIK
0000744218
Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.
Many of our clinical programs seek to leverage the power of the immune system’s response by combining therapeutic approaches to maximize their potential. Key to this strategy is our ability to understand our own asset base while also identifying promising external technologies that will complement it. In 2005, Celldex was spun out of the New Jersey based biopharmaceutical company Medarex (now a subsidiary of the Bristol-Myers Squibb Company) and, in connection with this transaction, Celldex retains the rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform. Since its inception, Celldex has also acquired four companies, folding in three assets, and in-licensed/purchased an additional two assets. With the potential for positive results in ongoing late stage programs, the next stage in Celldex’s development is to become a fully-integrated commercial entity.
Management:
http://www.celldextherapeutics.com/about/management.php
Product Pipeline:
http://www.celldextherapeutics.com/pipeline/pipeline-overview.php
News and Press Releases:
http://ir.celldextherapeutics.com/releases.cfm
http://finance.yahoo.com/q/h?s=CLDX+Headlines
Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals http://ir.celldex.com/releasedetail.cfm?ReleaseID=996743
Events and Presentations:
http://ir.celldextherapeutics.com/events.cfm
SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000744218&owner=exclude&count=40
Transfer Agent:
Computershare, Inc.
250 Royall Street
Canton, MA 02021
Phone: (US) 800-736-3001 / (Int’l) 781-575-2000
Share Structure:
See SEC filings
Investor Relations:
Sarah Cavanaugh
Vice President
Investor Relations & Corporate Communications
ir@celldextherapeutics.com
----------------------------------------------
Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals November 8, 2016
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
AI
